The Hong Kong Association of the Pharmaceutical Industry (HKAPI) submits this opinion paper, on behalf of its 33 member companies engaging in the research and development of novel pharmaceuticals, and providing 70% of treatment drugs in Hong Kong.

Please download the full position paper here: http://bit.ly/HKAPI_PolicyAddress2020